<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TOLAZINE- tolazoline hydrochloride injection </strong><br>LLOYD Inc. of Iowa<br></p></div>
<h1>Tolazine<span class="Sup">®</span><br> INJECTION<br> Tolazoline HCl, USP<br> 100 mg Tolazoline per mL<br> Sterile Solution</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First">NADA #140-994, Approved by FDA</p>
<p>Xylazine Reversing Agent and Antagonist</p>
<p>For Intravenous Use in Horses Only</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-2"></a><p></p>
<h1>CAUTION</h1>
<p class="First">Federal law restricts this drug to use by or on the order of a licensed veterinarian.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-3"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Tolazine contains tolazoline hydrochloride with the chemical name 1H-Imidazole,4,5-dihydro-2-(phenylmethyl)-monohydrochloride. Tolazoline hydrochloride has a molecular weight of 196.68 and the molecular formula is C<span class="Sub">10</span>H<span class="Sub">12</span>N<span class="Sub">2</span>•HCl. The structural formula is</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0b94baa5-5af2-46e9-8111-519225206a28&amp;name=tolazine-01.jpg"></div>
<p>Each mL contains: tolazoline hydrochloride equivalent to 100 mg base activity, chlorobutanol 5.0 mg, tartaric acid 7.8 mg, sodium citrate dihydrate 7.8 mg and water for injection. The pH is adjusted with hydrochloric acid and sodium citrate.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-4"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Tolazoline belongs to the synthetic group of alpha-adrenergic blocking agents known as the imidazoline derivatives.<span class="Sup">1</span> It is a mixed alpha-1 and alpha-2 adrenergic receptor antagonist that competitively inhibits alpha-adrenoceptors.<span class="Sup">2,3</span> Tolazoline is also a direct peripheral vasodilator that decreases the peripheral resistance and increases venous capacitance.<span class="Sup">3</span></p>
<p>Xylazine is an alpha-2 adrenergic agonist with sedative and analgesic properties related to central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. Administration of Tolazine reverses xylazine's central nervous system depressant effects resulting in rapid recovery from sedation. The competitive blocking of the alpha-2 adrenergic receptor by Tolazine displaces xylazine from these sites and thereby rapidly cancels the effect of the xylazine.<span class="Sup">4</span></p>
<p>Onset of arousal is usually apparent within 5 minutes of Tolazine administration, depending on the depth and duration of xylazine induced sedation.<span class="Sup">4</span></p>
</div>
<div class="Section" data-sectionCode="50745-9">
<a name="section-5"></a><p></p>
<h1>INDICATIONS</h1>
<p class="First">Tolazine should be used in horses when it is desirable to reverse the effects of sedation and <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> caused by xylazine.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-6"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The Tolazine dose is 4.0 mg/kg body weight or 1.8 mg/lb (4 mL/100 kg or 4 mL/220 lb) to reverse the sedative effects of xylazine. The carefully calculated dose of Tolazine should be given slowly by intravenous injection. Administration rate should approximate 1 mL/second.<span class="Sup">1,5</span></p>
<p>The table demonstrates the correct injection volume based on body weight:</p>
<table width="80%">
<col align="center" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<col align="center" valign="top" width="33%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Body Weight (kg)</th>
<th class="Rrule" align="center">Body Weight (lb)</th>
<th class="Rrule" align="center">Tolazine Injection Volume</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">250 kg</td>
<td class="Rrule" align="center">550 lb</td>
<td class="Rrule" align="center">10 mL</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">500 kg</td>
<td class="Rrule" align="center">1100 lb</td>
<td class="Rrule" align="center">20 mL</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7"></a><p></p>
<h1>SIDE EFFECTS</h1>
<p class="First">Temporary side effects of Tolazine may be mild increases in blood pressure; <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>; <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">peripheral vasodilatation</span>, evidenced by injected mucous membranes of the gingiva and conjunctiva; and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>. A few horses may show <span class="product-label-link" type="condition" conceptid="4031840" conceptname="Hyperesthesia">hyperalgesia</span> of the lips, evidenced by licking or flipping of the lips. Some horses may exhibit <span class="product-label-link" type="condition" conceptid="4224957" conceptname="Piloerection">piloerection</span> soon after dosing. Clear lacrimal and <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">nasal discharges</span> may be noted. <span class="product-label-link" type="condition" conceptid="4189159" conceptname="Muscle fibrillation">Muscle fasciculations</span> may be observed. Some horses may show signs of temporary apprehensiveness. All clinical side effects should dissipate within 60-120 minutes.</p>
<p>The potential for side effects increases when higher than recommended doses are given or when Tolazine is given without prior administration of xylazine.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">The safety of Tolazine has not been evaluated in horses with metabolically unstable conditions. Tolazine should not be administered to animals exhibiting signs of stress, debilitation, cardiac disease, sympathetic blockage, <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span> or <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>.</p>
<p>The safety of Tolazine has not been evaluated for reversing xylazine used as a preanesthetic to a general anesthetic.</p>
<p>The safety of Tolazine has not been established in pregnant mares, lactating mares, horses intended for breeding, or foals.</p>
<p>Tolazine should be administered carefully and at a slow rate to allow venous dilution to occur prior to the drug reaching the brain and heart. An administration rate of 1 mL/second was shown to be safe at the recommended dose.</p>
<p>Tolazine reverses the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effects</span> of xylazine as well as the sedative effects. If the animal was given xylazine for its analgesic properties, reversal may result in return of normal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> perception.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9"></a><p></p>
<h1>SAFETY</h1>
<p class="First">The safety of Tolazine alone without prior xylazine administration was evaluated in healthy horses. Tolazine was administered at 1, 3, and 5 times the recommended dose of 4 mg/kg, every 6 hours for 3 doses. When administered alone, Tolazine caused <span class="product-label-link" type="condition" conceptid="4010029" conceptname="Increased intestinal motility">gastrointestinal hypermotility</span> as horses defecated or attempted to defecate with <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span> within minutes after injection. Some horses exhibited <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span> (mild <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">colic</span>) and displayed transient <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disturbances</span> were seen in all dose groups.</p>
<p>The safety of Tolazine was evaluated following administration of xylazine in healthy horses. The frequency of <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span> was decreased in the presence of xylazine. Most horses experienced xylazine-induced hypomotility. A return to normal intestinal motility occurred within 5 minutes after Tolazine administration. A single incidence of mild <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">colic</span> was observed at three times the recommended Tolazine dose, and one instance of transient <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> was exhibited at three times the recommended Tolazine dose.</p>
<p>The heart rate may briefly increase immediately after Tolazine injection at the recommended dose with return to pretreatment rates within 5-10 minutes. The degree and duration of <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> increased with higher doses, although the increased rate usually lasted less than 60 minutes.</p>
<p>When Tolazine was administered at higher than the recommended dose in healthy horses, intraventricular conduction was slowed, as demonstrated by a prolongation of the <span class="product-label-link" type="condition" conceptid="4064625" conceptname="QRS complex feature">QRS complex</span> of the ECG. This effect was not observed at the 1× dose, only a mild prolongation occurred in a single horse at the 2× dose, and it was seen in most horses that received the 3× and 5× doses. Abnormalities of intraventricular conduction can predispose to <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span> and possibly <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdoses</span> of Tolazine at 5 times the recommended dose have been associated with fatalities in horses.</span></p>
<p>Tolazine reverses blood pressure reduction induced by xylazine in healthy horses, and may result in mild <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> in some animals at the recommended dose.</p>
<p>Tolazine at doses less than or equal to 5 times the recommended dose did not affect any hematologic, serum biochemical, or urinalysis measurements.</p>
</div>
<div class="Section" data-sectionCode="50743-4">
<a name="section-10"></a><p></p>
<h1>WARNING</h1>
<p class="First">Keep out of reach of children. Not for human use.</p>
<p>This drug is for use in horses only and not for use in food-producing animals.</p>
<p>Avoid contact with eyes, skin and mucous membranes. In case of eye contact flush with plenty of water. Exposed skin should be washed with soap and water. In case of accidental oral exposure or injection, seek emergency medical attention.</p>
<p>Users with cardiovascular disease (for example, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>) should take special precautions to avoid accidental exposure to this product.</p>
<p>To report adverse reactions in users or to obtain a copy of the material safety data sheet for this product, call 1-800-831-0004.</p>
<p>NOTE TO PHYSICIAN: This product contains an alpha-2 adrenoreceptor antagonist. Epinephrine should not be used to treat <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in humans resulting from exposure to this product since tolazoline may cause "epinephrine reversal" (further reduction in blood pressure, followed by an exaggerated rebound).</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11"></a><p></p>
<h1>STORAGE</h1>
<p class="First">Protect from light. Store at controlled room temperature 15° to 30°C (59° to 86°F).</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">100 mL multiple-dose vial.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-13"></a><p></p>
<h1>REFERENCES</h1>
<ol>
<li>Adams, H.R. <span class="Underline">Veterinary Pharmacology and Therapeutics</span>. Iowa State University Press, Ames, IA. 7th ed. 1995:104-108.</li>
<li>Short, C.E. Ed.: <span class="Underline">Principles and Practice of Veterinary Anesthesia</span>, Williams and Wilkins, Baltimore, MD, 1987.</li>
<li>Tranquilli, W.J. and Thurmon, J.C. Alpha adrenoceptor pharmacology. JAVMA 1984; 184:1400-1402.</li>
<li>LLOYD, Inc. Research, 1989-1995.</li>
<li>Hsu, W. H., et al. Effects of tolazoline and yohimbine on xylazine-induced central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span> in sheep. JAVMA 1987; 190:423-426.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14"></a><p></p>
<p class="First">Manufactured for:</p>
<p><span class="Bold">LLOYD<br>Laboratories</span><br>A Division of LLOYD, Inc.</p>
<p>Shenandoah, Iowa 51601- 0086 USA</p>
<p>Manufactured by<br>Akorn Manufacturing, Inc.<br>Decatur, IL 62525</p>
<p>October, 2007</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 100 mL Vial Label</h1>
<p class="First"><span class="Bold">Tolazine<span class="Sup">®</span><br> INJECTION</span></p>
<p>100 mL</p>
<p>Tolazoline HCl, USP<br>100 mg Tolazoline per mL</p>
<p>Xylazine Reversing Agent and Antagonist<br>for Intravenous Use in Horses Only</p>
<p>CAUTION: Federal law restricts this drug<br>to use by or on the order of a licensed<br>veterinarian.</p>
<p>NADA # 140-994, Approved by FDA</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 100 mL Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0b94baa5-5af2-46e9-8111-519225206a28&amp;name=tolazine-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TOLAZINE 		
					</strong><br><span class="contentTableReg">tolazoline hydrochloride injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PRESCRIPTION ANIMAL DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:61311-486</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TOLAZOLINE HYDROCHLORIDE</strong> (TOLAZOLINE) </td>
<td class="formItem">TOLAZOLINE</td>
<td class="formItem">100 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TARTARIC ACID</strong></td>
<td class="formItem">7.8 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRISODIUM CITRATE DIHYDRATE</strong></td>
<td class="formItem">7.8 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CHLOROBUTANOL</strong></td>
<td class="formItem">5 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:61311-486-10</td>
<td class="formItem">1  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">100 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NADA</td>
<td class="formItem">NADA140994</td>
<td class="formItem">04/19/1996</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>LLOYD Inc. of Iowa
							(007281942)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">LLOYD, Inc.</td>
<td class="formItem"></td>
<td class="formItem">007281942</td>
<td class="formItem">ANALYSIS</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Albany Molecular Research Limited</td>
<td class="formItem"></td>
<td class="formItem">738704498</td>
<td class="formItem">API MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>31aacb0e-090a-4448-a37e-7fb79caaa2b9</div>
<div>Set id: 0b94baa5-5af2-46e9-8111-519225206a28</div>
<div>Version: 1</div>
<div>Effective Time: 20111221</div>
</div>
</div> <div class="DistributorName">LLOYD Inc. of Iowa</div></p>
</body></html>
